Atopic dermatitis patients resistant to systemic treatment respond to tralokinumab
Click Here to Manage Email Alerts
Key takeaways:
- Patients with atopic dermatitis that were resistant to systemic therapies, including dupilumab, were treated with tralokinumab for 4 months.
- Patients improved across all efficacy categories.
MIAMI BEACH, Fla. — Patients with atopic dermatitis resistant to systemic therapy, including dupilumab, may benefit from tralokinumab treatment, according to a poster presentation here.
Elena Pezzolo, MD, of the department of dermatology at San Bortolo Hospital and the Study Center of the Italian Group for the Epidemiologic Research in Dermatology in Italy, won this year’s poster competition at South Beach Symposium for her research on the efficacy and safety profile of tralokinumab in patients with moderate to severe AD that were resistant to systemic therapies, including dupilumab.
In the case study, 36 patients were administered on-label tralokinumab 300 mg once every 2 weeks for a minimum of 4 months.
Results showed that all patients improved across all efficacy points once administered tralokinumab. After 4 months, the patients that were dupilumab-experienced achieved a mean IGA of 1.7, a large improvement from the baseline IGA of 3.7. Also, mean EASI scores decreased from 20.1 to 5.5, and Dermatology Quality of Life Index scores improved from 15.5 to 4.9.
Mean itch numerical rating scores among dupilumab-experienced patients also decreased from 7.8 to 2.7.
The non-dupilumab-experienced patients also saw an improvement in mean IGA score from baseline (4.6 vs. 1.5) and in EASI score from baseline (28.1 vs. 5). Dermatology Quality of Life Index scores also improved significantly from 16 at baseline to 4.5 after 4 months, whereas itch scores decreased from 9.5 to 2.1.
“This case series supports tralokinumab as a potentially effective therapy in patients with moderate to severe AD resistant to systemic therapy, including those who have discontinued dupilumab treatment due to lack of efficacy or [adverse events],” Pezzolo wrote.
Collapse
Pezzolo E. A retrospective case series of real-world tralokinumab use in patients with moderate to severe atopic dermatitis resistant to systemic therapy. Presented at: South Beach Symposium; Feb. 8-11, 2024; Miami Beach, Florida.
Read more about
Click Here to Manage Email Alerts